Retrospective Analysis of COVID-19 Vaccination in a University Hospital and the Relationship with the Epidemic Rate
DOI:
https://doi.org/10.33533/jpm.v16i2.4818Keywords:
Adult, epidemiology, vaccineAbstract
It was aimed to make a retrospective analysis of the vaccines administered in the vaccine unit of our hospital since the beginning of the COVID-19 pandemic. The study was carried out retrospectively from the vaccination records our hospital, 14 January 2021 to 01 July 2022. In the 18-month period, a total of 75079 (100%) vaccines were administered, 59386 (79%) were Biontech and 15693 (21%) were Sinovac vaccines. Only Sinovac was available until June, therefore, 66% of the Sinovac vaccines were administered in the first five months period. After the Biontech vaccine started to be applied in our hospital, the rates of Sinovac vaccination have declined drastically. When the epidemic and vaccination graphs were examined separately, inverse correlation was found between the peak points of the epidemic and vaccine graphics. Biontech was found to be the most preferred vaccine by individuals against COVID-19 in this study.
References
Weekly epidemiological update on COVID-19, 20 July 2022 (Internet). World Health Organization (WHO) (Access 20 July 2022). Available from
https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid19
Tracking Coronavirus vaccitanions araound the World (Internet). (Access 20 July 2022). Available from
https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html
Science Brief: COVID-19 vaccines and vaccination (Internet). Centers for disease control and prevention (CDC), (Access 20 July 2022). Available from
https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/fullyvaccinated-people.htm
Yap C, Ali A, Prabhakar A, Prabhakar A, Pal A, Lim YY, et al. Comprehensive literature review on COVID-19 vaccines and role of SARS-CoV-2 variants in the pandemic. Ther Adv Vaccines Immunother. 2021;(9):1-21.
Palacios R, Patino EG, Piorelli R de O, Conde MTRP, Batista AP, Zeng G, et al. Double-blind, randomized, placebo-cntrolled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (Inactivated) Vaccine manifactured by Sinovac- PROFISCOV: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(853):1-3.
Dagan N, Barda N, E Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412-23.
Genel Koronavirüs tablosu (Internet). ) (Access 20 July 2022).Available from
https://covid19.saglik.gov.tr/TR-66935/genel-koronavirus-tablosu.html
Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of nRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an abservational study using national surveiilance data. Lancet. 2021;(397):1819-29.
Paternina-Caicedo A, Jit M, Alvis-Guzman N, Fernandez JC, Hernandez J, Poz-Wilches JJ, et al. Effectiveness of CoronaVac and BNT162b2 COVID-19 mass vaccination in Colombia: A population-based cohort study. Lancet Reg Health Am. 2022;(12):1-9.
Akpolat T, Uzun O. Reduced mortality rate after coronavac vaccine among healtcare workers. J Infect. 2021;(83):750-2.
Uzun O, Akpolat T, Varol A, Turan S, Gokbulut-Bektas S, Cetinkaya PD, et al. COVID-19: Vaccination vs.hospitalization. Infection. 2022;(50):747-52.
Aw J, Seng JJB, Seah SSY, Low LL. COVID-19 vaccine hesitancy-a scoping review of literature in high-income countries. Vaccines. 2021;(9):900.
Chariyalertsak S, Intawong K, Chalom K, Wonghirundecha T, Thangprachum A, Chatirosniramit N, et al. Effectiveness of heterologous 3rd and 4th dose COVID-19 vaccine schedules for SARS-CoV-2 infection during delta and omicron predominance in Thailand. Research Square. 2022;1-15.
Voysey M, Clemens SAC, Madhi SA, Weck LY, Falegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;(397):99–111.
Köse E, Otura G, Ekerbiçer HÇ, Arslan A, Özaygın A, Nas B, Yavuz B, et al. Investigation of descriptive characteristics of randomized controlled trials of COVID-19 vaccines. Van Tıp Derg. 2022;29(1):76-83.
Mayr FB, Talisa VB,Shaikh O, Yende Sachin, Butt AA. Effectiveness of homologous or heterologous Covid-19 boosters in veterans. N Engl J Med. 2022;(386):1375-7.
Accorsi EK, Britton A, Shang N, Fleming-Dutra KE, Link-Gelles R, Smith ZR, Denado G,et al. Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron. N Engl J Med. 2022;386(25):2433-5.
Jing You, Nagma Shaik, Haihua Chen. ASIS⅋Annual Meeting 2021. Salt Lake City, UT.
Downloads
Published
How to Cite
Issue
Section
License
Copyright Notice
All articles submitted by the author and published in the Jurnal Profesi Medika : Jurnal Kedokteran dan Kesehatan, are fully copyrighted by the publication of Jurnal Profesi Medika : Jurnal Kedokteran dan Kesehatan under the Creative Commons Attribution-NonCommercial 4.0 International License by technically filling out the copyright transfer agreement and sending it to the publisher
Note :
The author can include in separate contractual arrangements for the non-exclusive distribution of rich versions of journal publications (for example: posting them to an institutional repository or publishing them in a book), with the acknowledgment of their initial publication in this journal.
Authors are permitted and encouraged to post their work online (for example: in an institutional repository or on their website) before and during the submission process because it can lead to productive exchanges, as well as earlier and more powerful citations of published works. (See Open Access Effects).
